Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment.
Cholestatic liver diseases, such as cystic fibrosis (CF) liver disease and biliary atresia, predominate as causes of childhood cirrhosis. Despite diverse etiologies, the stereotypic final pathway involves fibrogenesis where hepatic stellate cells (HSCs) are recruited, producing excess collagen which initiates biliary fibrosis. A possible molecular determinant of this recruitment, monocyte chemotaxis protein-1 (MCP-1), an HSC-responsive chemokine, was investigated in CF liver disease and biliary atresia. The bile-duct-ligated rat and in vitro coculture models of cholestatic liver injury were used to further explore the role of MCP-1 in HSC recruitment and proposed mechanism of induction via bile acids. In both CF liver disease and biliary atresia, elevated hepatic MCP-1 expression predominated in scar margin hepatocytes, closely associated with activated HSCs, and was also expressed in cholangiocytes. Serum MCP-1 was elevated during early fibrogenesis. Similar observations were made in bile-duct-ligated rat liver and serum. Hepatocytes isolated from cholestatic rats secreted increased MCP-1 which avidly recruited HSCs in coculture. This HSC chemotaxis was markedly inhibited in interventional studies using anti-MCP-1 neutralizing antibody. In CF liver disease, biliary MCP-1 was increased, positively correlating with levels of the hydrophobic bile acid, taurocholate. In cholestatic rats, increased MCP-1 positively correlated with taurocholate in serum and liver, and negatively correlated in bile. In normal human and rat hepatocytes, taurocholate induced MCP-1 expression.


CONCLUSIONS
These observations support the hypothesis that up-regulation of hepatocyte-derived MCP-1, induced by bile acids, results in HSC recruitment in diverse causes of cholestatic liver injury, and is a key early event in liver fibrogenesis in these conditions. Therapies aimed at neutralizing MCP-1 or bile acids may help reduce fibro-obliterative liver injury in childhood cholestatic diseases.
Ramm
Grant A
GA
The Hepatic Fibrosis Group, The Queensland Institute of Medical Research, Brisbane, Australia.
Shepherd
Ross W
RW
Hoskins
Anita C
AC
Greco
Sonia A
SA
Ney
Agnieszka D
AD
Pereira
Tamara N
TN
Bridle
Kim R
KR
Doecke
James D
JD
Meikle
Peter J
PJ
Turlin
Bruno
B
Lewindon
Peter J
PJ
D000818:Animals; D001706:Biopsy; D002465:Cell Movement; D018932:Chemokine CCL2 / Q000235:genetics / Q000502:physiology*; D002648:Child; D002675:Child, Preschool; D002780:Cholestasis, Intrahepatic / Q000473:pathology / Q000503:physiopathology*; D003550:Cystic Fibrosis / Q000473:pathology*; D017931:DNA Primers; D055166:Hepatic Stellate Cells / Q000473:pathology / Q000502:physiology; D022781:Hepatocytes / Q000473:pathology*; D006801:Humans; D008099:Liver / Q000473:pathology*; D051381:Rats; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013656:Taurocholic Acid / Q000502:physiology*
C491766:Ccl2 protein, rat; D018932:Chemokine CCL2; D017931:DNA Primers; D013656:Taurocholic Acid